Literature DB >> 25762349

Incidence and risk factors for hepatocellular carcinoma in primary biliary cirrhosis.

Guanghua Rong1, Hong Wang, Christopher L Bowlus, Chunping Wang, Yinying Lu, Zhen Zeng, Jianhui Qu, Min Lou, Yan Chen, Linjing An, Yongping Yang, M Eric Gershwin.   

Abstract

The incidence, risk factors, and clinical features of hepatocellular carcinoma (HCC) in primary biliary cirrhosis (PBC) have been a long-standing subject of interest. We took advantage of a large cohort of 1865 well-defined Chinese patients with PBC for whom follow-up was conducted for up to 20 years to study the incidence of HCC. Our goal was to address the incidence and prevalence of HCC in PBC and the risk factors, including hepatitis B virus (HBV) infection, and finally to compare the tumor characteristics of PBC-related HCC, including size, location, mortality, and long-term outcomes, to that of HBV-related HCC. In this cohort, HCC occurred in 70 of 1865 PBC patients with a prevalence of 3.75 % and an incidence of 0.66 cases per 100 patient-years. The 5- and 10-year cumulative incidences were 2.6 % (95 % confidence interval (CI) 1.8-3.4) and 8.9 % (95 % CI 5.5-12.3), respectively. Age >54 years (odds ratio [OR] = 5.5, 95 % CI 3.0-10.1, p = 0.001), male sex (OR = 2.2, 95 % CI 1.2-4.0, p = 0.001), co-existence of diabetes mellitus (DM) (OR = 3.1, 95 % CI 1.6-6.2, p = 0.002), and previous HBV infection (OR = 6.6, 95 % CI 3.7-11.9, p = 0.001) were independently associated with the development of HCC. The tumor size, number, location, and 5-year survival were not significantly different in PBC-related HCC compared to HBV-related HCC. Alpha-fetoprotein was elevated in only 20 % of the cases with PBC-related HCC. Although HCC was uncommon, occurring in fewer than 5 % of patients, the risk is significantly increased by age, sex, DM, and past HBV infection.

Entities:  

Mesh:

Year:  2015        PMID: 25762349     DOI: 10.1007/s12016-015-8483-x

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  38 in total

Review 1.  Current strategy for staging and treatment: the BCLC update and future prospects.

Authors:  Alejandro Forner; María E Reig; Carlos Rodriguez de Lope; Jordi Bruix
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

Review 2.  Disease-specific autoantibodies in primary biliary cirrhosis.

Authors:  Dimitrios P Bogdanos; Lars Komorowski
Journal:  Clin Chim Acta       Date:  2010-12-23       Impact factor: 3.786

Review 3.  Occult hepatitis B virus infection.

Authors:  Giovanni Raimondo; Teresa Pollicino; Irene Cacciola; Giovanni Squadrito
Journal:  J Hepatol       Date:  2006-11-07       Impact factor: 25.083

4.  Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid.

Authors:  Edith M M Kuiper; Bettina E Hansen; Rob P R Adang; Carin M J van Nieuwkerk; Robin Timmer; Joost P H Drenth; Piet Spoelstra; Hans T Brouwer; Johan P H Kuyvenhoven; Henk R van Buuren
Journal:  Eur J Gastroenterol Hepatol       Date:  2010-12       Impact factor: 2.566

5.  Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells.

Authors:  Wenting Huang; Kritika Kachapati; David Adams; Yuehong Wu; Patrick S C Leung; Guo-Xiang Yang; Weici Zhang; Aftab A Ansari; Richard A Flavell; M Eric Gershwin; William M Ridgway
Journal:  J Autoimmun       Date:  2014-02-18       Impact factor: 7.094

6.  Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.

Authors:  Kazuki Ikeda; Hiroyuki Marusawa; Yukio Osaki; Takefumi Nakamura; Naoto Kitajima; Yukitaka Yamashita; Masatoshi Kudo; Tosiya Sato; Tsutomu Chiba
Journal:  Ann Intern Med       Date:  2007-05-01       Impact factor: 25.391

7.  Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.

Authors:  Shigeru Adachi; Akitaka Shibuya; Yukiko Miura; Atsuko Takeuchi; Takahide Nakazawa; Katsunori Saigenji
Journal:  Scand J Gastroenterol       Date:  2008       Impact factor: 2.423

Review 8.  Mechanisms of tissue injury in autoimmune liver diseases.

Authors:  Evaggelia Liaskou; Gideon M Hirschfield; M Eric Gershwin
Journal:  Semin Immunopathol       Date:  2014-08-01       Impact factor: 9.623

9.  PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis.

Authors:  Alessandro Granito; Wei-Hong Yang; Luigi Muratori; Mark J Lim; Ayako Nakajima; Silvia Ferri; Georgios Pappas; Chiara Quarneti; Francesco B Bianchi; Donald B Bloch; Paolo Muratori
Journal:  Am J Gastroenterol       Date:  2009-10-27       Impact factor: 10.864

10.  Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells.

Authors:  Ana Lleo; Weici Zhang; W Hayes McDonald; Erin H Seeley; Patrick S C Leung; Ross L Coppel; Aftab A Ansari; David H Adams; Simon Afford; Pietro Invernizzi; M Eric Gershwin
Journal:  Hepatology       Date:  2014-07-31       Impact factor: 17.425

View more
  20 in total

1.  Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis.

Authors:  Na Zeng; Weijia Duan; Sha Chen; Shanshan Wu; Hong Ma; Xiaojuan Ou; Hong You; Yuanyuan Kong; Jidong Jia
Journal:  Hepatol Int       Date:  2019-09-25       Impact factor: 6.047

Review 2.  Xenobiotics and loss of tolerance in primary biliary cholangitis.

Authors:  Jinjun Wang; Guoxiang Yang; Alana Mari Dubrovsky; Jinjung Choi; Patrick S C Leung
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 3.  Geoepidemiology and changing mortality in primary biliary cholangitis.

Authors:  Annarosa Floreani; Atsushi Tanaka; Christopher Bowlus; Merrill Eric Gershwin
Journal:  J Gastroenterol       Date:  2017-04-01       Impact factor: 7.527

4.  CircMIIP Contributes to Non-Small Cell Lung Cancer Progression by Binding miR-766-5p to Upregulate FAM83A Expression.

Authors:  Tao Wang; Xu Zhu; Kai Wang
Journal:  Lung       Date:  2022-01-11       Impact factor: 2.584

5.  Hepatocellular carcinoma in primary sclerosing cholangitis and primary biliary cholangitis: a clinical and pathological study in an uncommon but emerging setting.

Authors:  Dustin E Bosch; Yoh Zen; Sarag A Boukhar; Yongjun Liu; Lin Cheng; Matthew M Yeh
Journal:  Virchows Arch       Date:  2021-08-20       Impact factor: 4.064

6.  Incidence of Hepatocellular Carcinoma in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.

Authors:  Yamini Natarajan; Aylin Tansel; Parth Patel; Kingsley Emologu; Richa Shukla; Zeeshan Qureshi; Hashem B El-Serag; Aaron P Thrift; Fasiha Kanwal
Journal:  Dig Dis Sci       Date:  2020-08-02       Impact factor: 3.199

7.  The Natural History and Prognosis of Primary Biliary Cirrhosis with Clinical Features of Autoimmune Hepatitis.

Authors:  Fan Yang; Qixia Wang; Zhaoyue Wang; Qi Miao; Xiao Xiao; Ruqi Tang; Xiaoyu Chen; Zhaolian Bian; Haiyan Zhang; Yue Yang; Li Sheng; Jingyuan Fang; Dekai Qiu; Edward L Krawitt; M Eric Gershwin; Xiong Ma
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 8.  Epigenetics and Primary Biliary Cirrhosis: a Comprehensive Review and Implications for Autoimmunity.

Authors:  Yu-Qing Xie; Hong-Di Ma; Zhe-Xiong Lian
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

Review 9.  Adaptive immunity in the liver.

Authors:  Zongwen Shuai; Miranda Wy Leung; Xiaosong He; Weici Zhang; Guoxiang Yang; Patrick Sc Leung; M Eric Gershwin
Journal:  Cell Mol Immunol       Date:  2016-03-21       Impact factor: 11.530

Review 10.  Recent advances in the diagnosis and treatment of primary biliary cholangitis.

Authors:  Ying-Qiu Huang
Journal:  World J Hepatol       Date:  2016-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.